The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of binimetinib with imatinib in patients with unresectable KIT-mutant melanoma.
 
Katy K. Tsai
Consulting or Advisory Role - Regeneron
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Oncosec (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Iwei Yeh
Research Funding - Array BioPharma/Pfizer (Inst)
 
Adil Daud
Stock and Other Ownership Interests - Trex bio
Honoraria - EMD Serono; Inovio Pharmaceuticals
Consulting or Advisory Role - Genoptix; GlaxoSmithKline; Merck; Oncosec
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Checkmate Pharmaceuticals; Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Merck/Schering Plough (Inst); Novartis; oncosec (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - patent relating to test for immunotherapy
 
Ari Oglesby
No Relationships to Disclose